{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:42:05Z","timestamp":1781196125533,"version":"3.54.1"},"reference-count":55,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Chronic Disease"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Numerous first-line immune checkpoint inhibitors (ICI) were developed for patients with advanced non-small cell lung cancer (NSCLC) lacking driver gene mutations. However, this group consists of a heterogeneous patient population, for whom the optimal therapeutic choice is yet to be confirmed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To identify the best first-line immunotherapy regimen for overall advanced NSCLC patients and different subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic review and Bayesian network meta-analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched several databases to retrieve relevant literature. We performed Bayesian NMA for the overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (tr-AEs) with a grade equal or more than 3 (grade\u2009\u2a7e\u20093 tr-AEs). Subgroup analysis was conducted according to programed death ligand 1 (PD-L1) levels, histologic type, central nervous system (CNS) metastases and tobacco use history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>For the PD-L1 non-selective patients, sintilimab plus chemotherapy (sinti-chemo) provided the best OS [hazard ratio (HR)\u2009=\u20090.59, 95% confidence interval (CI):0.42\u20130.83]. Nivolumab plus bevacizumab plus chemotherapy (nivo-bev-chemo) was comparable to atezolizumab plus bevacizumab plus chemotherapy (atezo-bev-chemo) in prolonging PFS (HR\u2009=\u20090.99, 95% CI: 0.51\u20131.91). Atezo-bev-chemo remarkably elevated the ORR than chemotherapy (OR\u2009=\u20093.13, 95% CI: 1.51\u20136.59). Subgroup analysis showed pembrolizumab plus chemotherapy (pembro-chemo) ranked first in OS in subgroups of PD-L1\u2009&lt;\u20091%, non-squamous, no CNS metastases, with or without smoking history, and ranked second in OS in subgroups of PD-L1\u2009\u2a7e\u20091% and PD-L1 1\u201349%. Cemiplimab and sugemalimab plus chemotherapy ranked first in OS and PFS for squamous subgroup, respectively. For patients with CNS metastases, nivolumab plus ipilimumab plus chemotherapy (nivo-ipili-chemo) and camrelizumab plus chemotherapy provided the best OS and PFS, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Sinti-chemo and nivo-bev-chemo were two effective first-line regimens ranked first in OS and PFS for overall patients, respectively. Pembro-chemo was favorable for patients in subgroups of PD-L1\u2009&lt;\u20091%, PD-L1\u2009\u2a7e\u20091%, PD-L1 1\u201349%, non-squamous, no CNS metastases, with or without smoking history. Addition of bevacizumab consistently provided with favorable PFS results in patients of all PD-L1 levels. Cemiplimab was the best option in squamous subgroup and nivo-ipili-chemo in CNS metastases subgroup due to their advantages in OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406223231189224","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:12:54Z","timestamp":1697001174000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of the profiles of first-line PD-1\/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-6290","authenticated-orcid":false,"given":"Fu","family":"Wenfan","sequence":"first","affiliation":[{"name":"Department of Chest Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China"},{"name":"Southern Medical University, Guangzhou, Guangdong, China"},{"name":"Department of Thoracic Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Manman","sequence":"additional","affiliation":[{"name":"Department of Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Xingyuan","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zeyong","sequence":"additional","affiliation":[{"name":"Department of Chest Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Jian","sequence":"additional","affiliation":[{"name":"Department of Chest Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Chest Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, 78 Hengzhigang Road, Guangzhou, Guangdong 510095, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"bibr1-20406223231189224","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"bibr2-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"bibr3-20406223231189224","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113543"},{"key":"bibr4-20406223231189224","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010122"},{"key":"bibr5-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-IO-S1-s05"},{"key":"bibr6-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"bibr7-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"bibr8-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1362"},{"key":"bibr9-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.016"},{"key":"bibr10-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000327"},{"key":"bibr11-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181c01fcb"},{"key":"bibr12-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16"},{"key":"bibr13-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.015"},{"key":"bibr14-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03579"},{"key":"bibr15-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493"},{"key":"bibr16-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.2130"},{"key":"bibr17-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"bibr18-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.019"},{"key":"bibr19-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.029"},{"key":"bibr20-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028"},{"key":"bibr21-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.023"},{"key":"bibr22-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.005"},{"key":"bibr23-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"bibr24-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.025"},{"key":"bibr25-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"bibr26-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz453.004"},{"key":"bibr27-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015"},{"key":"bibr28-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"bibr29-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0237"},{"key":"bibr30-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.008"},{"key":"bibr31-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"key":"bibr32-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009"},{"key":"bibr33-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.004"},{"key":"bibr34-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366"},{"key":"bibr35-20406223231189224","volume":"16","author":"Wang J","year":"2021","journal-title":"J Thorac Oncol"},{"key":"bibr36-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"bibr37-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014"},{"key":"bibr38-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30365-9"},{"key":"bibr39-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.180"},{"key":"bibr40-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.011"},{"key":"bibr41-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5367"},{"key":"bibr42-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.016"},{"key":"bibr43-20406223231189224","volume-title":"Proceedings of the annual meeting of the American association for cancer research 2020","author":"Zhang J","year":"2020"},{"key":"bibr44-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617941114"},{"key":"bibr45-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1724329"},{"key":"bibr46-20406223231189224","volume":"24","author":"Lee H","year":"2019","journal-title":"Molecules"},{"key":"bibr47-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"bibr48-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu098"},{"key":"bibr49-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.08.005"},{"key":"bibr50-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.9626"},{"key":"bibr51-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq020"},{"key":"bibr52-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.002"},{"key":"bibr53-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1038\/nri3064"},{"key":"bibr54-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-017-9552-y"},{"key":"bibr55-20406223231189224","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.07.005"}],"container-title":["Therapeutic Advances in Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223231189224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406223231189224","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223231189224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:19:45Z","timestamp":1777591185000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406223231189224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":55,"alternative-id":["10.1177\/20406223231189224"],"URL":"https:\/\/doi.org\/10.1177\/20406223231189224","relation":{},"ISSN":["2040-6223","2040-6231"],"issn-type":[{"value":"2040-6223","type":"print"},{"value":"2040-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"20406223231189224"}}